Sage Therapeutic (SAGE) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US78667J1088

Sage Therapeutics, a biopharmaceutical company traded on the NASDAQ under the symbol SAGE, focuses on developing and selling medications aimed at improving brain health. They have a diverse range of product candidates with innovative approaches to addressing various mental health conditions.

Among their key products, ZULRESSO is a controlled substance injection designed to treat postpartum depression in adults. Zuranolone, another promising compound, has advanced to Phase III trials for postpartum and major depressive disorders, while also being investigated for use in treatment-resistant depression, anxiety disorders, and bipolar depression.

Further expanding their portfolio, Sage Therapeutics is exploring SAGE-324, a compound currently in Phase II trials targeting essential tremors. They have also introduced SAGE-689, focusing on acute GABA hypofunction, and SAGE-718, an NMDA receptor modulator being tested for various conditions such as depression, Huntington's disease, and Alzheimer's.

Collaborations play a vital role in their development strategy. Notably, they have partnered with Shionogi & Co., Ltd. to enhance the presence of zuranolone in Japan, Taiwan, and South Korea. Additionally, a collaboration and license agreement with Biogen MA Inc. enables joint efforts in developing and marketing SAGE-217 and SAGE-324 products.

Established in 2010 and based in Cambridge, Massachusetts, Sage Therapeutics was originally known as Sterogen Biopharma, Inc. before rebranding in September 2011. For more information on their innovative treatments, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Sage Therapeutic (SAGE) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Sage Therapeutic (SAGE) - Stock Price & Dividends

SAGE Stock Overview

Market Cap in USD 933m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2014-07-18

SAGE Stock Ratings

Growth 5y -5.55
Fundamental -6.51
Dividend -
Rel. Performance vs Sector -12.49
Analysts 3.24/5
Fair Price Momentum 8.54 USD
Fair Price DCF -

SAGE Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

SAGE Growth Ratios

Growth 12m -73.50%
Growth Correlation 12m -42%
Growth Correlation 3m -91%
CAGR 5y -40.23%
Sharpe Ratio 12m -0.99
Alpha vs SP500 12m -99.97
Beta vs SP500 5y weekly 1.22
ValueRay RSI 11.24
Volatility GJR Garch 1y 62.10%
Price / SMA 50 -37.77%
Price / SMA 200 -46.35%
Current Volume 4315.9k
Average Volume 20d 989.5k

External Links for SAGE Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of SAGE stocks?
As of April 18, 2024, the stock is trading at USD 12.57 with a total of 4,315,890 shares traded.
Over the past week, the price has changed by -23.59%, over one month by -35.11%, over three months by -53.36% and over the past year by -72.54%.
What is the forecast for SAGE stock price target?
According to ValueRays Forecast Model, SAGE Sage Therapeutic will be worth about 9.6 in April 2025. The stock is currently trading at 12.57. This means that the stock has a potential downside of -23.79%.
Issuer Forecast Upside
Wallstreet Target Price 28 122.8%
Analysts Target Price 25.7 104.5%
ValueRay Target Price 9.6 -23.8%